Acinetobacter baumannii is an opportunistic human pathogen with the highest reported rates of multidrug resistance among Gram-negative pathogens. The capsular polysaccharide of A. baumannii is considered one of its most significant virulence factors providing resistance against complemented-mediated killing. Capsule synthesis in A. baumannii is usually initiated by the phosphoglycosyltransferase PglC. PglC transfers a phosphosugar from a nucleotide diphosphatesugar to a polyprenol phosphate generating a polyprenol diphosphate-linked monosaccharide. Traditionally, PglC was thought to have stringent specificity towards UDP-N-N′-diacetylbacillosamine (UDP-diNAcBac). In this work we demonstrate that A. baumannii PglC has the ability to utilize three different UDP-sugar substrates: UDP-N-acetylglucosamine (UDP-GlcNAc), UDP-N-acetylgalactosamine (UDP-GalNAc) or UDP-diNAcBac. Using phylogenetic analyses, we first demonstrate that A. baumannii PglC orthologs separate into three distinct clades. Moreover, all members within a clade are predicted to have the same preference for one of the three possible sugar substrates. To experimentally determine the substrate specificity of each clade, we utilized in vivo complementation models and NMR analysis. We demonstrate that UDP-diNAcBac is accommodated by all PglC orthologs, but some orthologs evolved to utilize UDP-GlcNAc or UDP-GalNAc in a clade-dependent manner. Furthermore, we show that a single point mutation can modify the sugar specificity of a PglC ortholog specific for UDP-diNAcBac and that introduction of a non-native PglC ortholog into A. baumannii can generate a new capsule serotype. Collectively, these studies begin to explain why A. baumannii strains have such highly diverse glycan repertoires.
Introduction
Many bacterial species produce and export high molecular weight polysaccharides, known as capsules. Capsular polysaccharides constitute a hydrophilic layer that surround and protect bacterial cells against environmental insults and, in the case of pathogenic species, from both the innate and adaptive host immune response. There is great diversity amongst capsular polysaccharides within single species. For example, Escherichia coli and Streptococcus pneumoniae produce more than 80 and 90 different capsular structures, respectively (Whitfield 2006; Geno et al. 2015) . The evolution of antigenically distinct capsular types in pathogenic bacteria is believed to be driven by selective pressure imposed by host immunity (Lipsitch 1999) .
Acinetobacter baumannii is among the most worrisome multidrug resistant nosocomial pathogens worldwide (Perez et al. 2007; Peleg et al. 2008; Tacconelli et al. 2017; Harding et al. 2018) . Acinetobacter baumannii is a frequent cause of nosocomial infections such as ventilator associated pneumonia and has also been identified as the causative agent of urinary tract infections (Valencia et al. 2009 ). Acinetobacter baumannii is able to form biofilms, withstand desiccation, and can survive at a wide range of temperatures and pH values which allow it to persist in healthcare environments (Bergogne-Berezin and Towner 1996; Vidal et al. 1996; Jawad et al. 1998; Cisneros and Rodriguez-Bano 2002; Tomaras et al. 2003; Montefour et al. 2008) . The capsular polysaccharide is considered one of the most important virulence factors employed by A. baumannii (Geisinger and Isberg 2015) . Moreover, the capsular polysaccharide is essential for survival in murine infection models, and mediates the remarkable resistance of A. baumannii to human complement (Russo et al. 2010; Lees-Miller et al. 2013) . Acinetobacter baumannii strains display extensive glycan diversity in their carbohydrate synthesis loci, with at least 77 serotypes identified (Di Nocera et al. 2011; Hu et al. 2013; Kenyon and Hall 2013; Scott et al. 2014) . Some of these capsules contain rare sugars such as 5,7-di-N-acetyl-acinetaminic acid, which has not previously been observed in nature (Kenyon et al. 2015a) . Despite this extraordinary variability in sugar composition, a vast majority of the capsules are predicted to be synthesized by the same pathway (Whitfield 2006) . This pathway starts with the addition of a phosphorylated monosaccharide onto an undecaprenyl-phosphate (Und-P) lipid carrier by a phosphoglycosyltransferase (PGT). Additional monosaccharides are subsequently added to complete the capsular subunit, which usually contain between three to six monosaccharides and are subsequently polymerized to form long polysaccharides via the activity of the Wzy polymerase (Whitfield 2006) . These capsule subunits can also be transferred to proteins via the activity of an O-oligosaccharyltransferase in the bacterial periplasm (Lees-Miller et al. 2013; Harding et al. 2015) . Further, A. baumannii does not contain an O antigen and thus, the surface of A. baumannii is dominated by lipooligosaccharide (LOS), capsule and O-glycoproteins (Kenyon and Hall 2013; Weber et al. 2015) .
PGTs are thought to be very specific for the monosaccharide they transfer. As an example, WecA is the archetype of the polyisoprenyl-phosphate N-acetylaminosugar-1-phosphate transferase (PNPT) family (Price and Momany 2005; Al-Dabbagh et al. 2008) . Members of this family are polytopic membrane proteins with more than 10 transmembrane helices. This family also includes Alg7, the UDP-N-acetylglucosamine (UDP-GlcNAc):dolichyl-phosphate (Dol-P) GlcNAc-1-P transferase that reside in the endoplasmic reticulum and initiate the synthesis of N-glycoproteins in eukaryotes (Barnes et al. 1984) . Both WecA and Alg7 are highly specific for GlcNAc, the first monosaccharide in their respective glycan synthesis cascade (Barnes et al. 1984; Lehrer et al. 2007 ). The Salmonella enterica PGT, WbaP, is the most studied polyisoprenyl-phosphate hexose-1-phosphate transferase (PHPT) and specifically transfers Galactose (Gal) to the phosphorylated lipid carrier (Wang et al. 1996; Patel et al. 2012b) . PHPTs are also polytopic membrane proteins with up to five transmembrane helices. Although these enzymes have five transmembrane segments, the C-terminal domain of WbaP (WbaP CT ) is sufficient for enzymatic activity (Patel et al. 2010 (Patel et al. , 2012a . WbaP CT is a monotopic transmembrane spanning protein with the C-terminal domain facing the cytosol, which is remarkably similar to the topology of the shortest PGT family identified so far, consisting of PglC orthologs found in Campylobacter and Acinetobacter species (Lukose et al. 2015) .
The most thoroughly studied PglC ortholog is from Campylobacter jejuni (PglC Cj ). PglC Cj transfers 2,4-diacetamido-2,4,6-trideoxy-D-Glc (QuiNAc4NAc) also known as N,N′-diacetylbacillosamine (diNAcBac) from UDP-diNAcBac to a phosphorylated lipid carrier. This is the first step in the synthesis of the N-heptasaccharide that decorates multiple proteins in C. jejuni (Linton et al. 2005; Glover et al. 2006) . Furthermore, in vitro analysis of PglC Cj and the PglC ortholog from A. baumannii strain AYE have demonstrated that both of these orthologs are specific for diNAcBac (Glover et al. 2006; Morrison and Imperiali 2013) . These findings would indicate that PglC orthologs have specificity for UDPdiNAcBac; however, PglC is the only PGT present in the genomes of A. baumannii strains possessing capsules with GlcNAc and GalNAc at the reducing end as well (Hu et al. 2013 ). This apparent contradiction was the starting point for this study.
Results

Acinetobacter baumannii PglC orthologs phylogenetically cluster into one of three clades
Analyses of the capsular polysaccharides from A. baumannii strains indicate that most structures contain GlcNAc, GalNAc or diNAcBac at their reducing ends (Hu et al. 2013; Lees-Miller et al. 2013; Morrison and Imperiali 2013; Scott et al. 2014) . Intriguingly, despite the presence of these three sugars at the reducing end, the genomes of most A. baumannii strains code for a single PGT, homologous to pglC from C. jejuni. However, PglC from the A. baumannii AYE strain is highly specific for diNAcBac in vitro, and is unable to transfer GlcNAc or GalNAc onto a phosphorylated lipid carrier (Morrison and Imperiali 2013) . One possibility to explain this apparent contradiction is that small changes in the amino acid sequence of PglC alter its sugar specificity. Therefore, a phylogenetic analysis was performed on A. baumannii PglC orthologs with substrate specificity predicted based on the glycan structures known to be present in these organisms. PglC orthologs clearly clustered into one of three phylogenetic clades (Figure 1 ). PglC orthologs that were predicted to utilize UDP-GlcNAc as a substrate all clustered together, as did those for UDP-GalNAc and UDPdiNAcBac, respectively. Three representative PglC orthologs were selected to experimentally test the substrate specificity of each PglC clade. Specifically, PglC from A. baumannii strain LUH3712 was selected as the representative "UDP-GlcNAc-specific" PGT, PglC from A. baumannii ATCC 17978 was selected as the representative "UDP-GalNAc-specific" PGT, and PglC from A. baumannii strain 1225 was selected as the representative "UDP-diNAcBac-specific" PGT. From this point forward, each PglC ortholog will be referred to as PglC GlcNAc (from strain 3712), PglC GalNAc (from strain 17978) or PglC diNAcBac (from strain 1225).
Testing for the ability of PglC orthologs to complement a model of E. coli O16 antigen synthesis
The E. coli O16 antigen repeat unit requires GlcNAc at the reducing end for subsequent polymerization into an O16 polysaccharide by the Wzy polymerase (Feldman et al. 1999 ). The first step in O16 antigen synthesis is dependent on WecA, a PNPT that exclusively transfers GlcNAc (Yao and Valvano 1994) . Therefore, to test for the ability of different PglC orthologs to transfer UDP-GlcNAc, we used an in vivo model of O16 antigen complementation in the E. coli CLM37 strain, which lacks the native PGT WecA. In addition, this strain lacks the WbbL rhamnosyltransferase required for the transfer of the second sugar of the O antigen subunit, and therefore wbbL was supplied in trans (Feldman et al. 1999) . CLM37 also lacks genes coding for proteins required for the biosynthesis of UDP-GalNAc as well as UDP-diNAcBac. Collectively, CLM37 is a model strain for assessing the ability of PGT enzymes to transfer UDP-GlcNAc.
As expected, PglC GlcNAc was able to complement the absence of WecA, as shown by the presence of the modal O antigen polysaccharide present in the LPS (Figure 2A) . Furthermore, western blotting probing with O16 specific anti-serum confirmed that the LPS was in fact O16 ( Figure 2B ), indicating that PglC GlcNAc is able to transfer UDP-GlcNAc in E. coli. PglC GalNac was able to partially complement the absence of WecA, as observed by the faint LPS ladder detected by silver staining and western blotting using O16 specific anti-serum ( Figure 2A and B, respectively). One possibility could have been that PglC GalNac was able to utilize UDP-GlcNAc also as a substrate. Alternatively, a modified O16 antigen containing another monosaccharide at the reducing end instead of GlcNAc could have been formed. To differentiate between these two possibilities, we analyzed the LPS of CLM37 coexpressing WbbL and PglC GalNAc by NMR. As seen in Figure 2D and Supplementary Figure S2 , the O antigen from the LPS purified from this strain had Phylogenetic analysis was performed on A. baumannii PglC orthologs with substrate specificity predicted based on the glycan structures known to be present in these organisms using the SeaView version 4 software with the parsimony circular presentation under default parameters (Gouy et al. 2010) . The red underlined PglC variants from A. baumannii strains LUH3712, ATCC 17978 and 1225 were chosen as representative PglC orthologs from each clade and are referred to as PglC GlcNAc , PglC GalNAc or PglC diNAcBac , respectively. Fig. 2 . In vivo complementation model for O16 antigen synthesis in a E. coli CLM37 ΔwecA mutant. (A) SDS-PAGE analysis of purified, silver stained LPS from E. coli CLM37 cells coexpressing WbbL (the rhamnosyltransferase expressed from pMF19) and either the vector control, PglC GlcNAc , PglC GalNAc or PglC diNAcBac . (B) Western blot analysis of the same purified LPS samples as in (A) probing for the E. coli O16 antigen using anti-O16 serum. (C) Western blot analysis of whole cell lysates probing for PglC and RNA polymerase expression levels. PglC variants were tagged with a hexa-histidine. RNA polymerase expression served as a loading control. (D) LPS was purified from CLM37 coexpressing WbbL and PglC GalNAc and analyzed via NMR. The chemical structure of the repeating O-antigen was found to be identical to the previously published structure for the E. coli O16 antigen.
the same structure as that published for wild-type K12 O16 expressing E. coli (Feldman et al. 1999) , demonstrating that PglC GalNAc can transfer GlcNAc in an E. coli model; however, levels of complementation in this model were poor when compared to CLM37 expressing PglC GlcNAc . Lastly, PglC diNAcBac was unable to restore O16 antigen synthesis as determined both by silver staining and western blotting. We confirmed that these results were not influenced by protein expression as all PglC orthologs were expressed at equivalent levels ( Figure 2C ).
Testing for the ability of PglC orthologs to complement a model of A. baumannii ATCC 17978 capsule synthesis Previously, we reported that A. baumannii ATCC 17978 requires PglC for both capsule and glycoprotein synthesis (Lees-Miller et al. 2013) . NMR analysis of the capsular polysaccharide from A. baumannii ATCC 17978 demonstrated that the reducing end sugar was GalNAc, indicating that the endogenous PglC ortholog in this strain prefers UDP-GalNAc as a substrate. Therefore, to test the ability of PglC orthologs to utilize UDP-GalNAc as a substrate, we introduced different pglC homologs into the A. baumannii 17978 ΔpglC mutant and probed for the restoration of capsule synthesis. As a caveat, UDP-GlcNAc is a precursor for UDP-GalNAc synthesis and is thus also available as a substrate in this model; however, A. baumannii ATCC 17978 lacks the genes coding for proteins required to synthesize UDP-diNAcBac.
As a negative control, the A. baumannii 17978 ΔpglC mutant was shown to lack all capsular polysaccharide when whole cell lysates were probed by western blot with anti-serum specific to the capsular polysaccharide of A. baumannii 17978 ( Figure 3A ). As expected, PglC GalNAc was able to complement the pglC mutation in this strain as evidenced by the restoration of capsular polysaccharide when analyzed by western blot ( Figure 3A ). PglC GlcNAc was also able to complement the pglC mutation in this strain; however, when analyzed by western blot the polysaccharide material migrated at an increased electrophoretic mobility indicating that the polysaccharide may contain less repeat units ( Figure 3A ). Last, PglC diNAcBac was not able to complement the A. baumannii 17978 ΔpglC mutant ( Figure 3A ). Again these results were not due to differences in PglC expression levels ( Figure 3B and C). Although western blotting with polyclonal anti-serum specific for the glycan of A. baumannii 17978 positively reacted with the proteinase K treated whole cell lysates of the 17978 ΔpglC strain expressing PglC GlcNAc , this observation could not ensure that GalNAc was incorporated at the reducing end sugar by the PglC GlcNAc variant. To unambiguously determine the reducing end sugar of the capsular polysaccharide in this strain, we purified polysaccharide and performed NMR analysis. We found the capsular polysaccharide purified from the A. baumannii 17978 ΔpglC strain expressing PglC GlcNAc was not identical to the native structure, which contained GalNAc at the reducing end (Lees-Miller et al. 2013) , and that instead, the reducing end sugar was GlcNAc ( Figure 3D and Supplementary Figure S3 ). These findings further support the notion that PglC GlcNAc prefers UDP-GlcNAc as a substrate. Importantly, the newly generated polysaccharide serotype produced by the A. baumannii 17978 ΔpglC strain expressing PglC GlcNAc was also able to provide resistance to complement mediated killing at similar levels observed by that of the A. baumannii 17978 ΔpglC strain expressing PglC GalNAc , the endogenous PglC ortholog from this strain (Supplementary Figure S4) .
In Figure 2 we demonstrated that the PglC GalNAc ortholog was able to provide minimal O16 complementation when expressed in E. coli, indicating that this enzyme may have weak activity towards UDP-GlcNAc. To determine if this was also observed in A. baumannii, we constructed a gne mutant in A. baumannii 17978 and tested for capsule production ( Figure 3A , last two panels). The gne gene codes for the epimerase that converts UDP-GlcNAc into UDPGalNAc (Bengoechea et al. 2002) . In this strain, UDP-GalNAc is not present leaving only UDP-GlcNAc as a sugar substrate. This strain was unable to produce capsule even though the native PGT (PglC GalNAc ) was still present, indicating that PglC GalNAc is specific for UDP-GalNAc when expressed in its natural setting in A. baumannii. Testing for the ability of PglC orthologs to transfer UDP-diNAcBac in an E. coli model As mentioned above, some A. baumannii PglC orthologs utilize UDP-diNAcBac as a substrate. To test for UDP-diNAcBac transfer, we constructed an E. coli strain using CLM37 as the background strain that heterologously expresses the enzymes required to synthesize UDP-diNAcBac, specifically, the PglD, PglE and PglF enzymes (Morrison and Imperiali 2013) . As previously mentioned, this strain also lacks wecA and the wbbL, thus, it cannot synthesize an O16 antigen. In this model, expression of a PglC ortholog would allow for transfer of a phosphorylated diNAcBac from UDP-diNAcBac to undecaprenyl-phosphate (P-Und) generating diNAcBac-PP-Und. This lipid-linked monosaccharide could then be transported to the periplasm and transferred to the outer core of a LOS by the WaaL ligase (Hug et al. 2010) . As seen in Figure 4A and B, all three PglC orthologs were able to generate LOS containing diNAcBac as determined by western blot analysis of purified LOS probing with the diNAcBac-specific Npg1 monoclonal antibody (Borud et al. 2010) . As a control, we expressed PglC diNAcBac in a double wecA/waaL mutant (Garcia-Quintanilla et al. 2014) , which is unable to transfer lipid-linked sugars to the outer core due to the absence of the WaaL O antigen ligase. As seen in the last lane of Figure 4A , lipid-A core was detected via silver stain; however, it did not react with the Npg1 antibody indicating the absence of diNAcBac ( Figure 4B , last lane). To confirm the presence of diNAcBac on the outer core, LOS was purified from CLM37 cells coexpressing the PglDEF enzymes as well as PglC GalNAc and subjected to NMR analysis. As seen in Figure 4D and Supplementary Figure S5 , diNAcBac was indeed attached to the outer core confirming the specificity of the Npg1 antibody as well as the functional ability of PglC orthologs from each clade to transfer diNAcBac.
The E96Q and T157V point mutations in PglC diNAcBac turn on specificity for UDP-GlcNAc Up to this point, our results indicate that PglC diNAcBac was only able to utilize UDP-diNAcBac as a substrate, whereas, PglC GalNAc and PglC GlcNAc were able to employ their cognate substrate and in addition, UDP-diNAcBac. To gain insights into the observed substrate specificities of each PglC clade, we compared the amino acid sequences of each PglC variant ( Figure 5A ). BLASTp analysis of PglC orthologs indicates that PglC GlcNAc and PglC GalNAc share higher sequence identity when compared to PglC diNAcBAc orthologs. Therefore, we selected amino acids, aside from those predicted to be in the transmembrane domain and the highly divergent C-terminal tail, that were conserved between PglC GlcNAc and PglC GalNAc orthologs, but different in PglC diNAcBac for point mutational analyses ( Figure 5A ). We also chose a few amino acids that were not conserved between all three PglC orthologs for mutational analysis. Interestingly, two point mutants, PglC diNAcBac [E96Q] and PglC diNAcBac [T157V] , gained the capability to utilize UDP-GlcNAc as a substrate as indicated by the complementation of O16 antigen synthesis ( Figure 5B and C) . To reiterate, in this model of GlcNAc transfer neither UDP-GalNAc nor UDP-diNAcBac are produced, thus the restoration of the O16 antigen strongly indicates that both PglC diNAcBac [E96Q] and PglC diNAcBac [T157V] are able to transfer GlcNAc. Neither point mutant was able to restore capsule synthesis in the A. baumannii 17978 ΔpglC model, further demonstrating that they are unable to use UDP-GalNAc as substrate ( Figure 5D ). Neither the E96Q nor the T157V mutations altered the ability of PglC diNAcBac to utilize UDP-diNAcBac as a substrate either ( Figure 5F and G). All other point mutants generated were unable to restore synthesis of O16 antigen and were not investigated further (Supplementary Figure S6) .
Glutamic acid at position 96 is a predictor for diNAcBac specificity in PglC orthologs
Based on our results and the phylogenetic analysis presented in Figure  1 and Supplementary Figure S1 , we predicted that any PglC ortholog containing glutamic acid (E) at position 96 would only utilize UDPdiNAcBac as a substrate. On the other hand, A. baumannii PglC orthologs containing glutamine (Q) at position 96 would prefer UDPGlcNAc or -GalNAc, yet, have the ability to utilize UDP-diNAcBac. Fig. 4 . In vivo complementation model for UDP-diNAcBac transfer. (A) SDS-PAGE analysis of purified, silver stained LPS from E. coli CLM37 coexpressing PglD, PglE and PglF (required to synthesis UDP-diNAcBac) as well as either the vector control, PglC GlcNAc , PglC GalNAc or PglC diNAcBac . The asterisk denotes LPS purified from the E. coli SDB1 strain, which lacks WecA and the WaaL ligase, coexpressing the pglDEF genes and pglC diNAcBac (B) Western blot analysis of the same purified LPS samples as in (A) probing for diNAcBac using the monoclonal Npg1 antibody. (C) Western blot analysis of whole cell lysates probing for PglC and RNA polymerase expression levels. PglC variants were tagged with a hexa-histidine. RNA polymerase expression served as a loading control. (D) LPS was purified from CLM37 coexpressing PglD, PglE, PglF as well as PglC GalNAc and analyzed via NMR. The outer core chemical structure was identical to the previously published structure for K12 E. coli with the addition of a single diNAcBac residue.
To assess this hypothesis, we tested three additional PglC orthologs each containing glutamic acid at position 96; furthermore, each of the following PglC orthologs falls within the PglC diNAcBac clade based on BLASTp analysis. We tested orthologs from Acinetobacter radioresistans strain SH164, Psychrobacter cryohalentis strain K5 and Thermus scotoductus strain K1. These three species were chosen as they are each more distantly related to A. baumannii; specifically, A. radioresistans is within the same genus of A. baumannii, P. cyrohalentis is within the same family as Acinetobacter (Moraxellaceae), and T. scotoducuts is a distantly related thermophilic bacterium. We experimentally confirmed that these enzymes only transfer UDPdiNAcBac ( Figure 6A and B) and were unable to transfer UDPGlcNAc or UDP-GalNAc (data not shown). Another Acinetobacter PglC ortholog from A. oleivorans strain DR1, which falls within the PglC GalNAc clade based on BLASTp analysis, contains a glutamine (Q) at position 96, and accordingly, it was also able to transfer diNAcBac ( Figure 6A and B) These data indicate that PglC orthologs containing glutamic acid at position 96 would prefer and only transfer UDP-diNAcBac.
PglC from C. jejuni, which contains Q at position 96, was shown to have a strong preference for UDP-diNAcBac in vitro (Das et al. 2017) . Accordingly, Figure 6D and E show that PglC from C. jejuni provides negligible levels of complementation in the E. coli O16 GlcNAc transfer model, confirming previously performed in vitro studies (Das et al. 2017) . This indicates that when position 96 is occupied by a Q, it is not possible to predict sugar specificity of a given PglC orthologue; however, when the entire PglC sequence is compared for sequence identity against the A. baumannii PglC clades presented above, we were able to accurately predict the sugar specificity of all PglC orthologues tested.
Discussion
Multidrug resistant A. baumannii strains are a global public health risk that has led the World Health Organization to categorize A. baumannii as a top priority for the research and development of new antimicrobial therapies (Tacconelli et al. 2017 ). The capsular polysaccharide of A. baumannii is one of its main virulence factors (Russo et al. 2010) . Although there is a tremendous variability in the structure of A. baumannii capsules, the gene coding the PGT PglC is present in the majority of A. baumannii genomes (discussed below). In this work, we utilized in vivo models of complementation and NMR analysis to investigate the specificity of PglC orthologs for different UDP-sugar substrates. Based on work in C. jejuni and the A. baumannii AYE strain, PglC was previously described to be specific for UDP-diNAcBac (Morrison and Imperiali 2013; Lukose et al. 2015) . However, we showed that some orthologs naturally transfer UDP-GlcNAc or UDP-GalNAc in their respective strains while retaining the ability to transfer UDP-diNAcBac in recombinant E. coli models. Furthermore, we demonstrate that single point mutations in a PglC ortholog specific for UDP-diNAcBac broaden the substrate specificity of this enzyme, enabling it to transfer UDPGlcNAc. Changes in the substrate specificity achieved by point mutations have only been described for glycosyltransferases, not PGTs. In the S. pneumoniae capsule serogroup 11, a single amino acid polymorphism at position 112 of WcrL is sufficient for this glycosyltransferase to incorporate UDP-Glc or UDP-GlcNAc at the nonreducing end and to generate a serotype switching from 11 A to 11D (Oliver et al. 2013) . Furthermore, the human beta 1,4-Gal transferase can be converted into beta 1,4-GalNAc transferase with a single Y284L mutation or an alpha 1,3-Gal transferase into alpha 1,3-GalNAc transferase by the triple mutations H280 L/T/S/A/G, A281G and A282G (Pasek et al. 2009 ). As mentioned above though, this is the first time that a single point mutation has been shown to expand the substrate repertoire of a PGT.
Capsules from E. coli, Salmonella enterica and S. pneumoniae predominately have the same reducing end sugar across strains, GlcNAc, Gal and Glc, respectively (Whitfield 2006; Geno et al. 2015) . A. baumannii strains, though, are capable of having at least four different reducing end sugars, GlcNAc (Hu et al. 2013) , GalNAc (Kenyon and Hall 2013) , diNAcBac (Morrison and Imperiali 2013) and N-acetylfucosamine (FucNAc) (Shashkov et al. 2015; Kenyon et al. 2015b) . The rare strains having FucNAc as the reducing end sugar can be readily identified bioinformatically by the presence of the ItrB1/ItrB3 PGT (Shashkov et al. 2015; Kenyon et al. 2015b) , which has high homology to WbpL orthologs from Pseudomonas aeruginosa (Dean et al. 1999 ). These enzymes have multiple transmembrane domains and are easily distinguishable from the short PGT family consisting of PglC orthologs. All the remaining A. baumannii strains carry a PglC ortholog transferring UDP-diNAcBac, UDP-GlcNAc or UDP-GlcNAc. UDP-diNAcBac is synthesized from UDP-GlcNAc (Morrison and Imperiali 2013) , so it makes sense that enzymes transferring this sugar are able to avoid UDP-GlcNAc, as this would result in sugar misincorporation and defects in capsule synthesis. On the contrary, there appears to be limited selective pressure for PglC orthologs specific for GlcNAc or GalNAc to avoid recognition of UDP-diNAcBac, as this nucleotidesugar is not synthesized in any strain examined so far with GalNAc or GlcNAc as the reducing end sugar, i.e. all strains of A. baumannii that contain GlcNAc or GalNAc at the reducing end do not contain diNABac anywhere in the glycan subunit.
In our E. coli model of O16 complementation (GlcNAc transfer model), we did observe that a PglC GalNAc was able to minimally complement WecA and transfer GlcNAc. However, when we assessed the ability of PglC GalNac to transfer GlcNAc in the A. baumannii 17978 Δgne mutant, we did not observe any GlcNAc transfer indicating that PglC GalNAc is indeed specific its cognate substrate in A. baumannii. We hypothesize that the low complementation levels detected in the E. coli experiment are due to the heterologous overexpression of the enzyme, as previously observed in similar complementation models (Patel et al. 2012b) .
NMR analysis showed that expression of PglC GlcNAc in an A. baumannii ATCC 17978 ΔpglC strain resulted in a new capsule structure containing GlcNAc instead of GalNAc, which is different than the structure we previously characterized when the endogenous PglC ortholog is present in A. baumannii ATCC 17978 (Lees-Miller et al. 2013) . For this to occur the second glycosyltransferase has to add the sugar Glucose (Glc) to the reducing end GlcNAc and the Wzy polymerase must also be able to polymerize capsules containing GlcNAc instead of GalNAc. In this particular case, we observed that the capsular polysaccharide contained less repeat units when compared to the wild-type given that it ran at an increased electrophoretic mobility ( Figure 3A) . As currently tested, we are unable to determine if the lower molecular weight polysaccharide is due to deficiencies in the PGT, downstream glycosyltransferase or the Wzy polymerase. Nevertheless, a similar relaxed polymerization reaction was observed in S. pneumoniae capsule serogroup 11. In that case, the Wzy polymerase can recognize Glc or GlcNAc at the nonreducing end (Oliver et al. 2013 ).
Recently, a ping-pong mechanism with a covalent enzyme intermediate was described for the PglC ortholog from C. jejuni (Das et al. 2017 ). The catalytic site was found to be constituted by the Asp-Glu dyad (positions 92 and 93, respectively), which is highly conserved in the PglC superfamily as well as in the PNPT and PHPT superfamilies (Lukose et al. 2015) . In this model, the active-site nucleophile D93 reacts with UDP-diNAcBac to form a covalent enzyme-substrate intermediate that undergoes a new nucleophilic attack by the Und-P to form Und-PP-diNAcBac in a second step. D156 is another highly conserved amino acid; yet, its role in catalysis is not clear. However, it could play a key role in the coordination of a metal ion co-factor or a structural role of the active site (Lukose et al. 2015) . Given the proximity of the two residues, Q96 and T157, to the previously characterized D93 and D156 residues, it is tempting to speculate that amino acid groups surrounding the catalytic site participate in the recognition of the UDP-sugar substrate. Our results presented here support this hypothesis that Q96E and T157V variants of PglC diNAcBac accommodate UDP-diNAcBac and UDP-GlcNAc in the active pocket but not UDP-GalNAc. We further speculate that this may be due to steric hindrance based on the stereochemistry of the C-4 carbon. Specifically, in UDP-diNAcBac and UDP-GlcNAc, the N-acetyl and hydroxyl groups, respectively, are equatorial to the ring while in UDP-GalNAc the C4 hydroxyl is axial (Pasek et al. 2009 ).
In conclusion, our results provide new insights into the evolution of PGTs, in particular of PglCs, and illustrate how single mutations can lead to the generation of new capsular serotypes. PglC is the only enzyme common in almost all A. baumannii strains and, in addition, is present in other important human and animal pathogens within the genus Campylobacter. Therefore, PglC is an attractive target for the design of new antimicrobials. Our results indicate that diverse PglC enzymes must be considered during the development of these potential inhibitors.
Materials and methods
Strains, plasmids and growth conditions
All strains used in this study are listed in Table I . Bacteria were grown at 37°C on L-agar or in LB broth. When appropriate, antibiotics were added at the following concentrations: 100 μg ampicillin/mL, 20 μg kanamycin/mL, 80 μg spectinomycin/mL. To induce protein expression, bacteria were grown to mid-logarithmic phase and supplemented with IPTG at a final concentration of 1 mM. Where appropriate, strains carrying variants of the pEC plasmid were induced with arabinose at a final concentration of 0.2%.
Cloning of pglC genes into pEXt20 and pEC
The pglC gene from A. baumannii 1225 was PCR amplified from genomic DNA using primer set 1. For a complete list of primer sets, please refer to the Supplementary Primer Table. The PCR product was purified, digested with BamHI and SalI (New England Biolabs), and then ligated into pEXT20, which was predigested with the same restriction enzymes. The ligation was transformed into DH5α and transformants were selected on L-agar supplemented with 100 μg ampicillin/mL. The pglC gene from A. baumannii 3712 was synthesized as a gene block from Integrated DNA Technologies. The gene block was cloned into pEXT20 using the In-Fusion Eco HDdry cloning kit from Takara using linearized pEXT20 amplified with primer set 3 as the plasmid vector following the manufacturers protocol. To clone each pglC homolog into pEC, primer sets 4, 5 and 6 were used. The PCR products were digested with HindIII/SalI (New England Biolabs) and then ligated into pEC, which was predigested with the same restriction enzymes. Transformants were selected on L-agar supplemented 20 μg kanamycin/mL.
Acinetobacter baumannii 17978 Δgne mutant and complement construction
The A. baumannii 17978Δgne mutant was constructed according to previously published methodologies (Tucker et al. 2014) . Briefly primer set 21 was used to amplify a kanamycin cassette flanked by FRT sites and 120 bp of homologous DNA 5′ and 3′ of the gne gene. This PCR product was electroporated into A. baumannii 17978 carrying pAT04, recombined into the gne locus, and subsequently flipped out using the pAT03 plasmid generating the in frame, FRT marked mutant. The A. baumannii 17978Δ gne mutant was complemented by introducing a copy of gne onto the pEC plasmid as described above for pEC-pglC constructs.
Complement killing assay for A. baumannii
Each A. baumannii strain was first grown overnight in 5 mL LB broth with appropriate antibiotics. The following day, each culture was diluted 1:100 in fresh LB broth with antibiotics and grown to mid-logarithmic phase, induced with 0.2% L-arabinose and grown overnight at 37°C. Aliquots equivalent to 0.15 OD 600 units of bacteria were centrifuged at 5000 × g for 10 min, washed in PBS, centrifuged again and resuspended in 150 μL of 10% pooled complement human serum (Innovative Research) as previously described (LeesMiller et al. 2013) . Serial 10-fold dilutions in 150 μL of serum were performed in a 96-well plate. The 96-well plate was sealed with parafilm and incubated for 3 h at 37°C and 10 μL aliquot was plated on LB agar from each well. Aliquot plates were incubated overnight at 37°C and assessed for growth. Heat-inactivated serum was made by heating serum at 56°C for 10 min. The experiment was performed in triplicate using two technical replicates of each strain.
Point mutation generation in pglC constructs
Point mutants in pglC diNAcBAc (from A. baumannii strain 1225) were generated using the QuikChange mutagenesis protocol. The complete list of primer sets used for point mutant PCRs can be found in Supplementary Table 1. Sequence verified plasmids were then introduced into electrocompetent CLM37 or A. baumannii 17978 ΔpglC cells.
Cloning of pglDEF genes into pEC
The pglDEF locus from A. baumannii 1225 genomic DNA was PCR amplified using primer set 20. The PCR product was purified and digested with XmaI and PstI, ligated into pEC that was predigested with the same restriction enzymes. The ligation was transformed into DH5α and transformants were selected on L-agar supplemented with 20 μg kanamycin/mL and subcultured for plasmid extraction.
LPS extraction
LPS was extracted following the methods of Marolda et al. (2006) . Precipitated LPS was resuspended in 50 μL of Laemmli buffer.
LPS silver staining
A 10 μL aliquot of LPS was first separated on a 15% SDS polyacrylamide gel. Silver staining of SDS-PAGE separated LPS was performed according to the methods of Tsai and Frasch (1982) .
Western blotting
A 10 μL aliquot of LPS, whole cell lysates or purified membranes was first separated on a 15% SDS polyacrylamide gel then transferred to a 0.22 micron nitrocellulose membrane. Membranes were blocked for 1 h at room temperature with Odyssey Blocking Buffer (TBS, Licor). Membranes were then incubated with primar antibody for 1 h in a 1:1 mixture of TBS supplemented with 0.1% Tween 20 pglC from A. oleivorans DR1 cloned into pEXT20 This study pEXT20-pglC A.radioresistans_SH164 pglC from A. radioresistans SH164 cloned into pEXT20 This study pEXT20-pglC P.cryohalentis_K5 pglC from P. cryohalentis K5 cloned into pEXT20 This study pEXT20-pglC T.scotoductus_K1 pglC from T. scotoductus K1 cloned into pEXT20 This study
and Odyssey Blocking Buffer. Antibodies were used at the following concentrations: O16 anti-serum (1:1000, Statens Serum Institut), A. baumannii 17978 glycan antisera (1:1000), Npg1 monoclonal antibody (1:10,000), anti-His (1:1000, Thermo PA1-983B) and anti-E. coli RNA polymerase alpha antibody (1:1000, Biolegend 663,104). Nitrocellulose membranes were washed three times with TBS supplemented with 0.1% Tween 20 then incubated with secondary antibody for 1 h. Secondary antibodies were used at the following concentrations: Goat anti-mouse IRDye 800CW (1:10,000, Licor) and Goat anti-rabbit IRDye 680RD (1:10,000, Licor). Nitrocellulose membranes were washed then imaged using the Licor Odyssey CLx instrument.
Total membrane preparations
Each A. baumannii strain was first grown overnight in 5 mL LB broth with appropriate antibiotics. The following day, each culture was diluted 1:100 in 25 mL LB broth with antibiotics and grown to mid-logarithmic phase, induced with IPTG and grown for an additional 3 h. Cells were pelleted, resuspended in TBS, and then lysed with three passages through a Constant Systems Cell Disruptor at 35,000 PSI. Lysates were centrifuged at 15,000 × g for 30 min and the supernatants were collected. The supernatants were ultracentrifuged at 100,000 × g for 1 h to pellet membranes. Membranes were resuspended in 100 μL Laemmli buffer and subsequently analyzed by western blotting as described above.
Extraction of polysaccharides for NMR analysis
Polysaccharides were extracted from E. coli cells by stirring cells in 45% phenol at 75°C for 20 min (2-3 g of dry cells in 200 mL). The whole mixture was dialyzed for several days in running tap water after which acetic acid was added to a final concentration of 10%. The precipitates were removed by centrifugation for 30 min at 8000 rpm. The supernatant was dialyzed against distilled water then lyophilized. Lyophilized polysaccharides were dissolved in 10 mL of 2% acetic acid and heated for 1-2 h at 100°C until a clear solution and precipitate formed. The reaction was cooled and the precipitate was removed by centrifugation at 10,000 rpm. The supernatant was separated on Biogel P6 column (2.5 × 60 cm 2 ) in 1% acetic acid subsequently dried. Alternatively, A. baumannii cells were directly hydrolyzed in 2% acetic acid at 100°C for 2 h. The sample was cooled and precipitates were removed by centrifugation. The soluble products were separated on a Biogel P6 column (2.5 × 60 cm 2 ) in 1% acetic acid subsequently dried. If needed, polysaccharides were purified by anion-exchange chromatography on a Hitrap Q column in a linear gradient of water to 1 M NaCl final concentration over 1 h.
NMR analysis details
NMR experiments were carried out on a Bruker AVANCE III 600 MHz ( 1 H) spectrometer with 5 mm Z-gradient probe with acetone internal reference (2.23 ppm for 1 H and 31.45 ppm for 13 C) using standard pulse sequences cosygpprqf (gCOSY), mlevphpr (TOCSY, mixing time 120 ms), roesyphpr (ROESY, mixing time 500 ms), hsqcedetgp (HSQC), hsqcetgpml (HSQC-TOCSY, 80 ms TOCSY delay) and hmbcgplpndqf (HMBC, 100 ms long range transfer delay). Resolution was kept at < 3 Hz/pt in F2 in protonproton correlations and < 5 Hz/pt in F2 of H-C correlations. The spectra were processed and analyzed using the Bruker Topspin 2.1 program.
Supplementary data
Supplementary data is available at GLYCOBIOLOGY online.
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